Penumbra Names Shruthi Narayan as President

August 27, 2025—Penumbra, Inc. announced the promotion of Shruthi Narayan to President of the company, effective September 1, 2025.

According to the company, Narayan will continue to report to Adam Elsesser, who previously served in the role of President and will continue in his roles as Chairman of the Board and Chief Executive Officer of Penumbra.

As noted in the press release, Narayan is a 20-year veteran of the medical device industry. Most recently, she served as president of Penumbra’s interventional business, leading day-to-day operations and overseeing growth initiatives for both the company’s neuro and vascular franchises. She joined Penumbra in 2013 as a product manager in the stroke franchise, then transitioned to help build the peripheral vascular division, globally commercializing Penumbra’s vascular portfolio of embolization and thrombectomy products.

The company further noted that Narayan began her medical device career at Medtronic in 2006, working in engineering, regulatory affairs and then in the cardiovascular sales organization. She received a BS in Electrical Engineering from Anna University in Chennai, India, and an MS in Biomedical Engineering with a focus on Medical Device Commercialization from the University of Southern California in Los Angeles, California.

“Penumbra has been at the forefront of blood clot care for more than 20 years, advancing the most innovative technologies to address conditions from head to toe, like stroke and pulmonary embolism,” stated Narayan in the press release. “I am honored to carry on and expand our legacy of innovation and look forward to continuing this paradigm shift in patient care.”

Also in the press release, Elsesser commented, “Shruthi is a dynamic, seasoned leader whose passion for innovation and proven ability to inspire global teams make her the obvious choice for this critical role. Her vision and focus on excellence will undoubtedly help sustain Penumbra’s exceptional growth and market leadership, expanding access to our life-saving technology to patients around the world.”